Abstract 232P
Background
An ongoing field of research examines the use of the proteasome genes as prognostic biomarkers in cancer. The cross talk between such machinery and VHL is well rectified, so it is of a great interest to study the prognostic utility of the 20S proteasome gene family in VHL-mutated ccRCC cohort.
Methods
Clinical and transcriptomics data of VHL-mutated ccRCC patients were obtained from the Cancer Genome Atlas Program (TCGA). A total of 11 genes of the 20S proteasome β-subunit (PSMB1-11) were retrieved and tested for their prognostic potential using multivariate Cox logistic regression. The immune suppressive landscape was viewed through the assessment of M2 macrophages (M2M), cancer-associated fibroblasts (CAF), T-regulatory cells (Tregs), and myeloid-derived suppressor cells (MDSC) infiltration using xCell. Correlations with T-cell exhaustion genes were performed additionally.
Results
A total of six genes exhibited significant prognostic indicators, including PSMB1 (HR: 2.113, 95% CI: 1.101-4.056, P = .024), PSMB2 (HR: 2.303, 95% CI: 1.168-4.542, P = .016), PSMB4 (HR: 2.165, 95% CI: 1.075-4.361, P = .031), PSMB6 (HR: 2.956, 95% CI: 1.458-5.998, P = .003), PSMB7 (HR: 2.168, 95% CI: 1.127-4.170, P = .020), and PSMB10 (HR: 2.227, 95% CI: 1.109-4.469, P = .024). Immunosuppressive cells infiltration analysis revealed the following significant correlations (P < .05): PSMB1: MDSC (ρ = 0.316), PSMB2: M2M (ρ = 0.242) and MDSC (ρ = 0.268), PSMB4: M2M (ρ = 0.159) and MDSC (ρ = 0.372), PSMB6: M2M (ρ = 0.247) and MDSC (ρ = 0.412), PSMB7: MDSC (ρ = 0.298), and PSMB10: M2M (ρ = 0.283) and MDSC (ρ = 0.271). No significant correlations were observed in CAF infiltration. Surprisingly, all the markers negatively correlated with Tregs infiltration. The prognostic genes followed a unified pattern of correlation with T-cell exhaustion genes in which positive significant correlations to CTLA4, LAG3, and GZMB were observed. In contrast, all the markers negatively correlated with CD274 (PD-L1) expression.
Conclusions
Several members of the 20S proteasome β-subunit gene family exhibit a prognostic role in VHL-mutated ccRCC and induce an immunosuppressive tumor microenvironment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract